Vertex to Present Phase 3 Data Highlighting Suzetrigine’s …
Oct 18, 2024 · Vertex recently initiated a Phase 3 pivotal program of suzetrigine in patients with painful diabetic peripheral neuropathy (DPN) and has completed enrollment in its Phase 2 study of suzetrigine in painful lumbosacral radiculopathy (LSR) — both are PNP conditions. Suzetrigine is investigational and has not been approved by any health authority.
Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine …
Jul 30, 2024 · Suzetrigine has the potential to be the first new class of medicine to treat acute pain in over twenty years. The FDA has granted suzetrigine priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 30, 2025.
Vertex Announces Advancements of Suzetrigine (VX-548) in …
Apr 18, 2024 · Vertex is now preparing to initiate a Phase 3 pivotal program of suzetrigine in patients with DPN in 2H 2024. In addition, the FDA recently granted suzetrigine Breakthrough Therapy designation for the treatment of pain associated with DPN.
Vertex pain data: Combo results, Vicodin miss and stellar safety
3 days ago · Vertex has reported phase 3 data on its near-approval pain drug candidate suzetrigine, shedding light on how the non-opioid painkiller combines with ibuprofen and why the prospect failed to...
Vertex Announces Positive Results From the VX-548 Phase 3 …
Jan 30, 2024 · BOSTON -- (BUSINESS WIRE)--Jan. 30, 2024-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from its Phase 3 program for the selective NaV1.8 inhibitor, VX-548, in the treatment of moderate-to-severe acute pain.
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s …
Oct 18, 2024 · Vertex recently initiated a Phase 3 pivotal program of suzetrigine in patients with painful diabetic peripheral neuropathy (DPN) and has completed enrollment in its Phase 2 study of...
Vertex Presents Phase 3 Data on Nonopioid Suzetrigine to Treat …
4 days ago · Suzetrigine, the investigational oral, highly selective NaV1.8 pain signal inhibitor for the treatment of acute pain in development by Vertex, was highlighted during 2 oral presentations at the annual meeting of the American Society of Anesthesiologists (ASA), taking place from October 18-22, 2024, in Philadelphia, PA, according to a company news release. 1
New Pain Medication Suzetrigine Prevents Pain Signals from …
Aug 20, 2024 · In January Vertex announced promising results of clinical trials of VX-548, which it is calling suzetrigine, showing that it dampened acute pain levels by about one half on that 0-to-10 scale....
Nonopioid Suzetrigine Demonstrates Positive Phase 3 Results for …
4 days ago · Most participants (83.2%) rated the effectiveness of suzetrigine for treating pain as good, very good, or excellent at the end of treatment. Poster presentations at ASA marked the first public disclosure of positive phase 3 clinical trial results for suzetrigine since developer Vertex Pharmaceuticals’ January 2024 announcement of trial ...
Vertex’s blockbuster-in-waiting painkiller suzetrigine set for FDA ...
Jul 31, 2024 · The US Food and Drug Administration (FDA) has accepted Vertex Pharmaceuticals’ completed new drug application (NDA) submission for suzetrigine, as the company’s non-opioid-based treatment for...
- Some results have been removed